



(11) **EP 2 525 817 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 72, 73

(48) Corrigendum issued on:
20.09.2017 Bulletin 2017/38

(45) Date of publication and mention
of the grant of the patent:
09.08.2017 Bulletin 2017/32

(21) Application number: **11735230.2**

(22) Date of filing: **21.01.2011**

(51) Int Cl.:
A61K 39/145^(2006.01)

(86) International application number:
PCT/US2011/022062

(87) International publication number:
WO 2011/091255 (28.07.2011 Gazette 2011/30)

(54) **VACCINE VECTORS AND METHODS OF ENHANCING IMMUNE RESPONSES**

IMPfstoffvektoren und Verfahren zur Verstärkung von Immunreaktionen
Vecteurs de vaccin et procédés d'amplification de réponses immunitaires

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **21.01.2010 US 297098 P**

(43) Date of publication of application:
28.11.2012 Bulletin 2012/48

(73) Proprietors:
• **The Board of Trustees of The University of
Arkansas
Little Rock, AR 72207 (US)**
• **The Texas A&M University System
College Station, TX 77843-3369 (US)**

(72) Inventors:
• **BERGHMAN, Luc
College Station, TX 77845 (US)**
• **BOTTJE, Walter
Fayetteville, AR 72703 (US)**
• **HARGIS, Billy
Fayetteville, AR 72764 (US)**
• **LAYTON, Sherryll
Rogers, AR 72758 (US)**

(74) Representative: **Kremer, Simon Mark et al
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE (GB)**

(56) References cited:
**WO-A2-2008/036675 WO-A2-2008/036675
US-A1- 2003 165 538 US-A1- 2008 004 207
US-A1- 2008 030 520 US-A1- 2008 069 821
US-A1- 2008 305 120**

• **KIMURA R ET AL: "Enhancement of antibody
response by high mobility group box
protein-1-based DNA immunization", JOURNAL
OF IMMUNOLOGICAL METHODS, ELSEVIER
SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL,
vol. 361, no. 1-2, 30 September 2010 (2010-09-30),
pages 21-30, XP027301012, ISSN: 0022-1759
[retrieved on 2010-05-12]**
• **MAURIELLO E M F ET AL: "Display of
heterologous antigens on the Bacillus subtilis
spore coat using CotC as a fusion partner",
VACCINE, ELSEVIER LTD, GB, vol. 22, no. 9-10,
12 March 2004 (2004-03-12), pages 1177-1187,
XP004493381, ISSN: 0264-410X, DOI:
10.1016/J.VACCINE.2003.09.031**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 525 817 B8

- **SAENZ R ET AL: "HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 47, 3 November 2010 (2010-11-03), pages 7556-7562, XP027434019, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2010.08.054 [retrieved on 2010-08-25]**
- **ROVERE-QUERINI ET AL.: 'HMGB1 is an endogenous immune adjuvant released by necrotic cells.' EMBO REP vol. 5, no. 8, August 2004, pages 825 - 830**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification